Table 1.

Genomic abnormalities of the FGFR pathway in cancer

Gene		Cancer	Prevalence (%)
FGFR1	Amplification	Hormone receptor positive breast cancer	10–15 [20]
		Squamous NSCLC	10–20 [21]
		Urothelial cancer	9–10 [7]
		Squamous cell carcinoma of the head and neck	10–17 [22]
		Oesophageal squamous cell carcinoma	9 [23]
		Osteosarcoma	5 [11]
FGFR2	Amplification	Gastric cancer	5–10 [24]
		Triple negative breast cancer	4 [25]
	Mutation	Squamous NSCLC	3–5 [26]
		Endometrial cancers	12 [27]
FGFR3	Amplification	Urothelial cancer	3–5 [7]
	Translocation	Multiple myeloma	20 [28]
		Glioblastoma	3–7 [29]
	Mutation	Non-invasive urothelial cancer	38–66 [6, 9]
		Invasive urothelial cancer	15–20 [6–8]

FGFR fibroblast growth factor receptor, NSCLC non-small-cell lung cancer